Chemotherapy-induced peripheral neuropathy (CIPN) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

The United States was 557,125 in 2020 and by 2030 it will reach up to 589,544. The incidence diagnosed cases of CIPN in the USA are expected to increase at a CAGR of 0.5% during the study period of 2020 to 2030

Chemotherapy-induced peripheral neuropathy (CIPN) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Comprehensive insight on patient segmentation based on age, sex, Chemotherapy agent type, Pain types (Neuropathy-associated pain, Peripheral mechanisms, Central mechanisms, Inflammatory mechanisms), Stages (Mild, Moderate & Severe), Signs & Symptoms, Clini-cal Manifestations, Treatment types (SNRI, Alpha-2-delta antagonist, Opioid analgesics, Tricyclic antidepressants & others) has been provided into the epidemiology (Incidence and Prevalence) section of the CIPN and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key assets among these are, PledOx; PledPharma AB, Hal-neuron (Tetrodotoxin or TTX); WEX Pharmaceuticals Inc, APX3330; Apexian Pharmaceuticals, Inc., MN-166; MediciNova, Inc. Apart from the above companies like Asahi Kasei Corporation, Mundipharma, Midatech Pharma, Regenacy Pharmaceuticals, Apexian Pharmaceuticals, KannaLife Sciences, Jazz Pharmaceuticals, Emerald Bioscience, Noxopharm Limited, Aptinyx, Inc. and BMS having their assets under the early phase of development. Pfizer and Purdue Pharma developing their products outside the USA in collaborations with Asahi Kasei Corporation and Mundipharma International. Some of the critical assets are being suspended due to a lack of satisfactory study outcomes.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Other Reports:-
Cytomegalovirus (CMV) infection – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Advanced pancreatic ductal adenocarcinoma (PDAC) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Perivascular epithelioid cell tumors (PEComa) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Ischemia Reperfusion Injury (IRI) – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Refractory CD19+ B-cell malignancies – Market outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: CIPN, Chemotherapy-induced peripheral neuropathy (CIPN), Chemotherapy-induced peripheral neuropathy (CIPN) market outlook report, Chemotherapy-induced peripheral neuropathy (CIPN) competitive landscape, Chemotherapy-induced peripheral neuropathy (CIPN) market forecast See Campaign: https://thelansis.com/reports/chemotherapy-induced-peripheral-neuropathy-cipn-market-outlook-report/
Contact Information:
m.berg@thelansis.com

Tags:
Reportedtimes, PR-Wirein, iCN Internal Distribution, Research Newswire, English